| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| NADPH Oxidase 2 | 14 | 2020 | 58 | 6.06 | Why? |
| Oxidative Stress | 20 | 2020 | 2050 | 3.28 | Why? |
| Olive Oil | 5 | 2019 | 46 | 3.14 | Why? |
| Lipopolysaccharides | 6 | 2021 | 848 | 2.26 | Why? |
| Hypoalbuminemia | 3 | 2021 | 235 | 2.12 | Why? |
| Antioxidants | 9 | 2020 | 1593 | 1.93 | Why? |
| Portal Vein | 4 | 2019 | 193 | 1.86 | Why? |
| Liver Cirrhosis | 9 | 2019 | 1810 | 1.71 | Why? |
| Chocolate | 2 | 2019 | 23 | 1.57 | Why? |
| Blood Platelets | 8 | 2021 | 1704 | 1.54 | Why? |
| Aspirin | 5 | 2021 | 1043 | 1.34 | Why? |
| Conjunctivitis | 2 | 2021 | 318 | 1.26 | Why? |
| Receptors, Thrombopoietin | 2 | 2018 | 23 | 1.26 | Why? |
| Tobacco Smoke Pollution | 2 | 2018 | 181 | 1.18 | Why? |
| Iridoid Glucosides | 2 | 2019 | 4 | 1.03 | Why? |
| Vitamin E | 4 | 2018 | 128 | 1.01 | Why? |
| Vascular Diseases | 3 | 2020 | 846 | 0.99 | Why? |
| Thrombophilia | 3 | 2020 | 1935 | 0.98 | Why? |
| Intestinal Mucosa | 2 | 2021 | 1046 | 0.91 | Why? |
| Thrombosis | 6 | 2021 | 7504 | 0.91 | Why? |
| Atherosclerosis | 4 | 2019 | 768 | 0.89 | Why? |
| NADPH Oxidases | 4 | 2017 | 80 | 0.89 | Why? |
| Isoprostanes | 3 | 2018 | 22 | 0.87 | Why? |
| Diet, Mediterranean | 4 | 2018 | 351 | 0.86 | Why? |
| Haptoglobins | 1 | 2021 | 117 | 0.84 | Why? |
| Atrial Fibrillation | 12 | 2018 | 2320 | 0.84 | Why? |
| Diet, Diabetic | 1 | 2019 | 7 | 0.83 | Why? |
| Food, Fortified | 1 | 2019 | 43 | 0.80 | Why? |
| Esophageal and Gastric Varices | 2 | 2018 | 117 | 0.79 | Why? |
| Dinoprost | 3 | 2017 | 49 | 0.79 | Why? |
| Venous Thrombosis | 4 | 2019 | 2739 | 0.78 | Why? |
| Carotid Artery Diseases | 3 | 2019 | 251 | 0.78 | Why? |
| Endotoxemia | 1 | 2021 | 143 | 0.78 | Why? |
| Thromboembolism | 3 | 2021 | 2101 | 0.77 | Why? |
| Corylus | 1 | 2018 | 7 | 0.77 | Why? |
| Iridoids | 1 | 2018 | 3 | 0.76 | Why? |
| Platelet Aggregation | 3 | 2018 | 318 | 0.75 | Why? |
| Estrogen Replacement Therapy | 1 | 2018 | 50 | 0.73 | Why? |
| Community-Acquired Infections | 4 | 2019 | 2328 | 0.70 | Why? |
| Thromboxane A2 | 1 | 2017 | 17 | 0.70 | Why? |
| Hyperglycemia | 2 | 2019 | 1363 | 0.69 | Why? |
| Toll-Like Receptor 4 | 2 | 2018 | 390 | 0.69 | Why? |
| Endotoxins | 1 | 2017 | 80 | 0.67 | Why? |
| Protein Precursors | 1 | 2021 | 425 | 0.67 | Why? |
| Plaque, Atherosclerotic | 3 | 2018 | 423 | 0.66 | Why? |
| Dilatation | 1 | 2018 | 181 | 0.66 | Why? |
| Cyclooxygenase Inhibitors | 2 | 2017 | 46 | 0.66 | Why? |
| Oxidoreductases | 1 | 2017 | 136 | 0.65 | Why? |
| Glucose Intolerance | 1 | 2018 | 115 | 0.65 | Why? |
| Coronary Artery Disease | 4 | 2021 | 2570 | 0.64 | Why? |
| Arteries | 1 | 2018 | 283 | 0.61 | Why? |
| CD40 Ligand | 2 | 2006 | 121 | 0.61 | Why? |
| Platelet Aggregation Inhibitors | 4 | 2019 | 1671 | 0.61 | Why? |
| Gonadal Steroid Hormones | 1 | 2018 | 328 | 0.60 | Why? |
| Factor VIII | 1 | 2017 | 229 | 0.58 | Why? |
| Postprandial Period | 3 | 2019 | 45 | 0.58 | Why? |
| Reactive Oxygen Species | 2 | 2018 | 1136 | 0.56 | Why? |
| Blood Glucose | 2 | 2019 | 3642 | 0.55 | Why? |
| Thromboxanes | 2 | 2018 | 7 | 0.54 | Why? |
| Nitric Oxide | 2 | 2018 | 769 | 0.54 | Why? |
| Cardiovascular Diseases | 10 | 2020 | 11497 | 0.52 | Why? |
| Blood Coagulation | 4 | 2021 | 2768 | 0.52 | Why? |
| Escherichia coli | 2 | 2018 | 1547 | 0.51 | Why? |
| Coronary Thrombosis | 1 | 2017 | 433 | 0.49 | Why? |
| Smokers | 1 | 2018 | 550 | 0.48 | Why? |
| Hydrazines | 1 | 2012 | 68 | 0.47 | Why? |
| Myocardial Infarction | 5 | 2021 | 3361 | 0.47 | Why? |
| Thrombocytopenia | 2 | 2018 | 2093 | 0.47 | Why? |
| Benzoates | 1 | 2012 | 102 | 0.47 | Why? |
| Arteriosclerosis | 3 | 2011 | 50 | 0.46 | Why? |
| Anticoagulants | 10 | 2021 | 9563 | 0.45 | Why? |
| Hemorrhage | 5 | 2019 | 3013 | 0.45 | Why? |
| von Willebrand Factor | 1 | 2017 | 668 | 0.44 | Why? |
| Platelet Transfusion | 1 | 2012 | 209 | 0.44 | Why? |
| Cross-Over Studies | 3 | 2019 | 867 | 0.44 | Why? |
| Rhinitis, Allergic | 1 | 2018 | 704 | 0.44 | Why? |
| Intestines | 1 | 2017 | 817 | 0.43 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.43 | Why? |
| Platelet Activation | 4 | 2019 | 660 | 0.42 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.41 | Why? |
| Dietary Supplements | 3 | 2020 | 2251 | 0.40 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.40 | Why? |
| Gastrointestinal Microbiome | 3 | 2017 | 1961 | 0.40 | Why? |
| Blood Coagulation Disorders | 2 | 2020 | 2040 | 0.39 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 1261 | 0.38 | Why? |
| Cerebrovascular Disorders | 1 | 2017 | 1040 | 0.37 | Why? |
| Biomarkers | 12 | 2021 | 23361 | 0.37 | Why? |
| Thromboxane B2 | 2 | 2018 | 23 | 0.37 | Why? |
| Fibrinolytic Agents | 1 | 2020 | 1702 | 0.36 | Why? |
| Rome | 3 | 2019 | 497 | 0.36 | Why? |
| Sterol Esterase | 2 | 2017 | 4 | 0.36 | Why? |
| Non-alcoholic Fatty Liver Disease | 4 | 2018 | 907 | 0.36 | Why? |
| Patient Compliance | 2 | 2017 | 1468 | 0.35 | Why? |
| alpha-Linolenic Acid | 1 | 2006 | 7 | 0.34 | Why? |
| Macrophages | 2 | 2018 | 2784 | 0.32 | Why? |
| Liver Diseases | 3 | 2019 | 2698 | 0.32 | Why? |
| Fatty Liver | 1 | 2010 | 299 | 0.32 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.31 | Why? |
| Disease Progression | 4 | 2018 | 13580 | 0.31 | Why? |
| Female | 46 | 2021 | 380317 | 0.31 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.31 | Why? |
| Plant Oils | 1 | 2006 | 86 | 0.31 | Why? |
| Humans | 73 | 2021 | 930598 | 0.31 | Why? |
| Male | 45 | 2021 | 367725 | 0.30 | Why? |
| Weight Loss | 1 | 2011 | 826 | 0.29 | Why? |
| Hypercholesterolemia | 1 | 2006 | 175 | 0.28 | Why? |
| Endothelium, Vascular | 2 | 2018 | 1751 | 0.28 | Why? |
| Polyphenols | 2 | 2018 | 283 | 0.28 | Why? |
| Ultrasonography, Doppler | 2 | 2019 | 406 | 0.27 | Why? |
| Platelet Count | 3 | 2020 | 1381 | 0.27 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.27 | Why? |
| Hydrogen Peroxide | 3 | 2018 | 680 | 0.27 | Why? |
| Analysis of Variance | 3 | 2018 | 950 | 0.26 | Why? |
| Risk | 4 | 2020 | 5288 | 0.26 | Why? |
| Pneumonia | 3 | 2019 | 5652 | 0.25 | Why? |
| Pyrazoles | 2 | 2017 | 1791 | 0.25 | Why? |
| Metabolic Syndrome | 1 | 2011 | 810 | 0.25 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.25 | Why? |
| Aged | 30 | 2021 | 215776 | 0.24 | Why? |
| Kaplan-Meier Estimate | 4 | 2021 | 4260 | 0.24 | Why? |
| Middle Aged | 29 | 2021 | 270681 | 0.24 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.24 | Why? |
| Healthy Volunteers | 2 | 2018 | 1444 | 0.23 | Why? |
| Insulin Resistance | 2 | 2018 | 669 | 0.23 | Why? |
| Peripheral Arterial Disease | 2 | 2018 | 471 | 0.23 | Why? |
| Italy | 13 | 2019 | 38444 | 0.22 | Why? |
| Stroke | 4 | 2021 | 8839 | 0.22 | Why? |
| Aging | 1 | 2017 | 3581 | 0.22 | Why? |
| Venous Thromboembolism | 2 | 2018 | 4273 | 0.21 | Why? |
| Permeability | 1 | 2021 | 238 | 0.21 | Why? |
| Fibrin Fibrinogen Degradation Products | 3 | 2021 | 5993 | 0.21 | Why? |
| Breast Neoplasms | 1 | 2018 | 3633 | 0.21 | Why? |
| Collagen Type IV | 1 | 2019 | 12 | 0.20 | Why? |
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2019 | 16 | 0.20 | Why? |
| Proportional Hazards Models | 4 | 2021 | 6543 | 0.20 | Why? |
| Proprotein Convertase 9 | 2 | 2018 | 141 | 0.20 | Why? |
| Propranolol | 1 | 2019 | 36 | 0.20 | Why? |
| Glucagon-Like Peptide 1 | 1 | 2019 | 83 | 0.19 | Why? |
| International Normalized Ratio | 2 | 2018 | 300 | 0.19 | Why? |
| Double-Blind Method | 3 | 2018 | 5988 | 0.19 | Why? |
| Cotinine | 1 | 2018 | 22 | 0.19 | Why? |
| Time Factors | 7 | 2019 | 31397 | 0.19 | Why? |
| Ascorbic Acid | 1 | 2005 | 676 | 0.19 | Why? |
| Acenocoumarol | 1 | 2018 | 22 | 0.19 | Why? |
| Risk Factors | 17 | 2019 | 71621 | 0.18 | Why? |
| Drug Administration Routes | 1 | 2018 | 106 | 0.18 | Why? |
| Nitrous Oxide | 1 | 2018 | 58 | 0.18 | Why? |
| Albumins | 1 | 2020 | 324 | 0.18 | Why? |
| Partial Thromboplastin Time | 1 | 2020 | 436 | 0.18 | Why? |
| Food Quality | 1 | 2018 | 49 | 0.18 | Why? |
| Hypertension, Portal | 1 | 2019 | 73 | 0.18 | Why? |
| Weibel-Palade Bodies | 1 | 2017 | 9 | 0.18 | Why? |
| Vitamin K | 2 | 2018 | 263 | 0.18 | Why? |
| Prothrombin Time | 1 | 2020 | 434 | 0.18 | Why? |
| Group IV Phospholipases A2 | 1 | 2017 | 14 | 0.18 | Why? |
| Catalase | 1 | 2018 | 97 | 0.18 | Why? |
| Statistics, Nonparametric | 2 | 2018 | 1008 | 0.18 | Why? |
| Granulomatous Disease, Chronic | 1 | 2017 | 60 | 0.17 | Why? |
| Rivaroxaban | 2 | 2019 | 467 | 0.17 | Why? |
| Endarterectomy, Carotid | 1 | 2018 | 78 | 0.17 | Why? |
| Antibodies, Anticardiolipin | 1 | 2019 | 208 | 0.17 | Why? |
| Dose-Response Relationship, Drug | 2 | 2017 | 3776 | 0.17 | Why? |
| Cyclic AMP | 1 | 2017 | 76 | 0.17 | Why? |
| Atrial Natriuretic Factor | 1 | 2017 | 75 | 0.17 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.17 | Why? |
| Carotid Arteries | 1 | 2019 | 182 | 0.17 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.17 | Why? |
| Biological Availability | 1 | 2018 | 388 | 0.16 | Why? |
| Menopause | 1 | 2018 | 136 | 0.16 | Why? |
| Aged, 80 and over | 16 | 2021 | 88759 | 0.16 | Why? |
| Carotid Intima-Media Thickness | 1 | 2018 | 179 | 0.16 | Why? |
| Liver Failure | 1 | 2020 | 266 | 0.16 | Why? |
| Myocardial Revascularization | 1 | 2019 | 267 | 0.16 | Why? |
| Functional Food | 1 | 2018 | 122 | 0.16 | Why? |
| Calcium Signaling | 1 | 2017 | 133 | 0.16 | Why? |
| Pneumonia, Viral | 7 | 2021 | 243684 | 0.16 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.16 | Why? |
| Lipase | 1 | 2017 | 153 | 0.16 | Why? |
| p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 230 | 0.15 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.15 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 286 | 0.15 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.15 | Why? |
| Single-Blind Method | 1 | 2019 | 1283 | 0.15 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.15 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.15 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2017 | 6166 | 0.14 | Why? |
| Multivariate Analysis | 4 | 2019 | 5440 | 0.14 | Why? |
| Linear Models | 2 | 2018 | 1914 | 0.14 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 372 | 0.14 | Why? |
| Endothelium | 1 | 2018 | 460 | 0.14 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.14 | Why? |
| Gene Expression | 1 | 2005 | 3332 | 0.14 | Why? |
| Cardiology | 2 | 2020 | 2873 | 0.14 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 436 | 0.13 | Why? |
| Antibodies, Antiphospholipid | 1 | 2019 | 519 | 0.13 | Why? |
| Incidence | 8 | 2019 | 25622 | 0.13 | Why? |
| Blood Pressure Determination | 1 | 2017 | 450 | 0.13 | Why? |
| Cross-Sectional Studies | 7 | 2019 | 53120 | 0.13 | Why? |
| Troponin | 1 | 2020 | 1058 | 0.13 | Why? |
| Secondary Prevention | 1 | 2019 | 762 | 0.13 | Why? |
| Arterial Occlusive Diseases | 1 | 2018 | 363 | 0.13 | Why? |
| Warfarin | 1 | 2018 | 402 | 0.13 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.13 | Why? |
| Lower Extremity | 1 | 2019 | 593 | 0.13 | Why? |
| Spleen | 1 | 2017 | 877 | 0.13 | Why? |
| DNA, Bacterial | 1 | 2017 | 835 | 0.12 | Why? |
| Risk Assessment | 6 | 2020 | 25439 | 0.12 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2004 | 1380 | 0.12 | Why? |
| Fasting | 1 | 2018 | 555 | 0.12 | Why? |
| Antiphospholipid Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Myeloid Cells | 1 | 2017 | 808 | 0.12 | Why? |
| Dipeptidyl Peptidase 4 | 1 | 2019 | 1061 | 0.12 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.11 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.11 | Why? |
| Mutation, Missense | 1 | 2017 | 863 | 0.11 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.11 | Why? |
| Sex Factors | 2 | 2019 | 11014 | 0.11 | Why? |
| Protective Factors | 1 | 2017 | 1720 | 0.11 | Why? |
| Internal Medicine | 1 | 2017 | 557 | 0.11 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2017 | 669 | 0.11 | Why? |
| Insulin | 1 | 2019 | 1316 | 0.10 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.10 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.10 | Why? |
| Hospitals, Pediatric | 1 | 2021 | 1792 | 0.10 | Why? |
| Adult | 12 | 2019 | 244371 | 0.10 | Why? |
| Peptide Fragments | 1 | 2020 | 2075 | 0.10 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.10 | Why? |
| Follow-Up Studies | 5 | 2019 | 17020 | 0.09 | Why? |
| Immunomodulation | 1 | 2018 | 1472 | 0.09 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.09 | Why? |
| Confidence Intervals | 1 | 2011 | 744 | 0.09 | Why? |
| Statistics as Topic | 1 | 2011 | 370 | 0.09 | Why? |
| Gastroenterology | 1 | 2019 | 1352 | 0.09 | Why? |
| Membrane Proteins | 1 | 2017 | 1733 | 0.08 | Why? |
| Endothelial Cells | 1 | 2017 | 2048 | 0.08 | Why? |
| Chronic Disease | 2 | 2019 | 5139 | 0.08 | Why? |
| Phospholipases A | 1 | 2005 | 3 | 0.08 | Why? |
| Hospitals, University | 1 | 2019 | 4173 | 0.08 | Why? |
| Superoxides | 1 | 2005 | 36 | 0.08 | Why? |
| Arachidonic Acids | 1 | 2005 | 36 | 0.07 | Why? |
| Protein Kinase C | 1 | 2005 | 58 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2019 | 3755 | 0.07 | Why? |
| Child | 3 | 2021 | 70012 | 0.07 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.07 | Why? |
| Dementia | 1 | 2019 | 1861 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Noninvasive Ventilation | 1 | 2017 | 2329 | 0.07 | Why? |
| Lipid Peroxidation | 1 | 2004 | 114 | 0.07 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.07 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.07 | Why? |
| Dried Blood Spot Testing | 2 | 2017 | 383 | 0.07 | Why? |
| Collagen | 1 | 2005 | 222 | 0.06 | Why? |
| Arrhythmias, Cardiac | 1 | 2017 | 2510 | 0.06 | Why? |
| Membrane Glycoproteins | 1 | 2012 | 2273 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Body Mass Index | 2 | 2017 | 4306 | 0.06 | Why? |
| Thrombin | 1 | 2005 | 325 | 0.06 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.06 | Why? |
| Clinical Competence | 1 | 2017 | 3263 | 0.06 | Why? |
| Registries | 2 | 2019 | 12327 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2019 | 6537 | 0.06 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Nutritional Status | 1 | 2011 | 1403 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Cohort Studies | 3 | 2017 | 36005 | 0.05 | Why? |
| Ascites | 1 | 2019 | 65 | 0.05 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 1510 | 0.05 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2019 | 107 | 0.05 | Why? |
| Biosynthetic Pathways | 1 | 2018 | 97 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Mental Status and Dementia Tests | 1 | 2019 | 208 | 0.04 | Why? |
| Outpatients | 1 | 2011 | 3417 | 0.04 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.04 | Why? |
| Myofibroblasts | 1 | 2017 | 61 | 0.04 | Why? |
| Infant | 1 | 2021 | 30274 | 0.04 | Why? |
| Food-Drug Interactions | 1 | 2017 | 24 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Angioplasty | 1 | 2018 | 106 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Ankle Brachial Index | 1 | 2017 | 53 | 0.04 | Why? |
| Platelet Function Tests | 1 | 2018 | 231 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.04 | Why? |
| Organ Size | 1 | 2017 | 384 | 0.04 | Why? |
| Indoles | 1 | 2005 | 1243 | 0.04 | Why? |
| Endpoint Determination | 1 | 2018 | 344 | 0.04 | Why? |
| Respiratory Insufficiency | 1 | 2017 | 7301 | 0.04 | Why? |
| Perioperative Period | 1 | 2017 | 276 | 0.04 | Why? |
| Animals | 3 | 2018 | 78931 | 0.04 | Why? |
| Dabigatran | 1 | 2017 | 204 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2019 | 21571 | 0.04 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.03 | Why? |
| Hospital Mortality | 1 | 2019 | 22087 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2004 | 2483 | 0.03 | Why? |
| Antithrombins | 1 | 2017 | 353 | 0.03 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.03 | Why? |
| Retrospective Studies | 3 | 2019 | 105322 | 0.03 | Why? |
| Thiazoles | 1 | 2017 | 496 | 0.03 | Why? |
| Factor Xa Inhibitors | 1 | 2017 | 490 | 0.03 | Why? |
| Stem Cells | 1 | 2017 | 595 | 0.03 | Why? |
| Regression Analysis | 1 | 2019 | 2484 | 0.03 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2019 | 1887 | 0.03 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.03 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.03 | Why? |
| Down-Regulation | 1 | 2017 | 1416 | 0.03 | Why? |
| Propensity Score | 1 | 2019 | 2690 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.02 | Why? |
| Congresses as Topic | 1 | 2019 | 1347 | 0.02 | Why? |
| Health Care Surveys | 1 | 2019 | 2942 | 0.02 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Bayes Theorem | 1 | 2019 | 3237 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 1454 | 0.02 | Why? |
| Thrombolytic Therapy | 1 | 2018 | 2218 | 0.02 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2004 | 10649 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Feeding Behavior | 1 | 2017 | 1909 | 0.02 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.02 | Why? |
| Liver | 1 | 2017 | 4007 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.01 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2019 | 6551 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.01 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.01 | Why? |
| Length of Stay | 1 | 2019 | 11042 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
| Young Adult | 1 | 2019 | 93724 | 0.01 | Why? |